OBJECTIVES: Mitochondrial toxicity is believed to be the main reason for adverse effects related to nucleoside reverse transcriptase inhibitors (NRTIs). The aim of the present study was to compare mitochondrial toxicity in NRTI-treated HIV-positive patients, HIV-positive treatment-naïve patients and HIV-negative controls by comparing mitochondrial DNA (mtDNA) copies/cell in peripheral blood mononuclear cells (PBMCs) and lactate/pyruvate (L/P) ratios in the different groups. METHODS: We enrolled 60 participants in the study: 31 patients on combined antiretroviral therapy (CART), 14 HIV-positive treatment-naive patients and 15 HIV-negative controls. mtDNA (copies/cell) in peripheral blood was analysed using quantitative real-time polymerase chain reaction (PCR). Standard curves and serial dilutions of plasmid-cloned mitochondrion and retinoblastoma (RB1) PCR products with known concentrations were generated to estimate the mtDNA and nuclear DNA (nDNA) copy numbers in each sample. The L/P ratio was enzymatically and spectrophotometrically analysed in samples from individuals in a fasted, non-exercise state. Results The median mtDNA copy number was 63 copies/cell (interquartile range 33-94) in HIV-positive patients and 153 (132-283) in HIV-negative controls (P<0.001). No significant difference was seen between the HIV-positive NRTI-exposed patients and the HIV-positive treatment-naive patients. Current use of didanosine was negatively correlated with depletion of mtDNA (r=-0.36, P=0.046). HIV-positive patients also had a higher L/P ratio compared with HIV-negative controls (P=0.004). CONCLUSIONS: The number of mtDNA copies/cell in PBMCs was depleted in HIV-positive treatment-naive patients as well as in HIV-positive NRTI-exposed patients. HIV-positive patients also had a higher L/P ratio compared with HIV-negative controls, which supports this conclusion. The study suggests that neither mtDNA in PBMCs nor L/P ratio is a good marker of NRTI-associated mitochondrial toxicity.
OBJECTIVES: Mitochondrial toxicity is believed to be the main reason for adverse effects related to nucleoside reverse transcriptase inhibitors (NRTIs). The aim of the present study was to compare mitochondrial toxicity in NRTI-treated HIV-positive patients, HIV-positive treatment-naïve patients and HIV-negative controls by comparing mitochondrial DNA (mtDNA) copies/cell in peripheral blood mononuclear cells (PBMCs) and lactate/pyruvate (L/P) ratios in the different groups. METHODS: We enrolled 60 participants in the study: 31 patients on combined antiretroviral therapy (CART), 14 HIV-positive treatment-naive patients and 15 HIV-negative controls. mtDNA (copies/cell) in peripheral blood was analysed using quantitative real-time polymerase chain reaction (PCR). Standard curves and serial dilutions of plasmid-cloned mitochondrion and retinoblastoma (RB1) PCR products with known concentrations were generated to estimate the mtDNA and nuclear DNA (nDNA) copy numbers in each sample. The L/P ratio was enzymatically and spectrophotometrically analysed in samples from individuals in a fasted, non-exercise state. Results The median mtDNA copy number was 63 copies/cell (interquartile range 33-94) in HIV-positive patients and 153 (132-283) in HIV-negative controls (P<0.001). No significant difference was seen between the HIV-positive NRTI-exposed patients and the HIV-positive treatment-naive patients. Current use of didanosine was negatively correlated with depletion of mtDNA (r=-0.36, P=0.046). HIV-positive patients also had a higher L/P ratio compared with HIV-negative controls (P=0.004). CONCLUSIONS: The number of mtDNA copies/cell in PBMCs was depleted in HIV-positive treatment-naive patients as well as in HIV-positive NRTI-exposed patients. HIV-positive patients also had a higher L/P ratio compared with HIV-negative controls, which supports this conclusion. The study suggests that neither mtDNA in PBMCs nor L/P ratio is a good marker of NRTI-associated mitochondrial toxicity.
Authors: Cecilia M Shikuma; Mariana Gerschenson; Dominic Chow; Daniel E Libutti; John H Willis; James Murray; Roderick A Capaldi; Michael Marusich Journal: AIDS Res Hum Retroviruses Date: 2008-10 Impact factor: 2.205
Authors: A C Ross; T Leong; A Avery; M Castillo-Duran; H Bonilla; D Lebrecht; U A Walker; N Storer; D Labbato; A Khaitan; I Tomanova-Soltys; G A McComsey Journal: HIV Med Date: 2011-11-21 Impact factor: 3.180
Authors: Asha R Kallianpur; Mariana Gerschenson; Todd Hulgan; Harpreet Kaur; David B Clifford; David W Haas; Deborah G Murdock; Justin C McArthur; David C Samuels; David M Simpson Journal: AIDS Res Hum Retroviruses Date: 2018-08-22 Impact factor: 2.205
Authors: Todd Hulgan; Gregory K Robbins; Spyros A Kalams; David C Samuels; Benjamin Grady; Robert Shafer; Deborah G Murdock; Doug Selph; David W Haas; Richard B Pollard Journal: PLoS One Date: 2012-08-27 Impact factor: 3.240
Authors: Pere Domingo; Javier Torres-Torronteras; Virginia Pomar; Marta Giralt; Joan Carles Domingo; Maria Del Mar Gutierrez; José M Gallego-Escuredo; Maria Gracia Mateo; Pedro Cano-Soldado; Irene Fernandez; Marçal Pastor-Anglada; Francesc Vidal; Francesc Villarroya; Antoni Andreu; Ramon Marti Journal: PLoS One Date: 2010-11-15 Impact factor: 3.240
Authors: Sophie Monnot; Nadine Gigarel; David C Samuels; Philippe Burlet; Laetitia Hesters; Nelly Frydman; René Frydman; Violaine Kerbrat; Benoit Funalot; Jelena Martinovic; Alexandra Benachi; Josué Feingold; Arnold Munnich; Jean-Paul Bonnefont; Julie Steffann Journal: Hum Mutat Date: 2011-01 Impact factor: 4.878
Authors: Deborah M Money; Emily C Wagner; Evelyn J Maan; Tessa Chaworth-Musters; Izabelle Gadawski; Julie E van Schalkwyk; John C Forbes; David R Burdge; Arianne Y K Albert; Zoe Lohn; Hélène C F Côté Journal: PLoS One Date: 2015-08-06 Impact factor: 3.240